Hobson Prior’s Post

🔍Spotlight of The Day: Women's Health Diagnostics Market🌐 📊 Path to Growth: Embark on a journey through the global #WomenHealth #Diagnosticsmarket, where expansion is on the horizon. Set to surge by USD 13,350.14 million, this dynamic market is projected to flourish with a robust CAGR of 7.93% between 2022 and 2027. 💡 STDs Under the Lens: Delving into #SexuallyTransmittedDiseases (#STDs), it's clear that the impacts are uneven, often disproportionately affecting women. Over 30 distinct #bacteria, #viruses, and #parasites drive the narrative, impacting pelvic health and fertility. 🏥 Breaking Down the Segments: The market's diversity shines through as we explore its segments. From #BreastCancer testing to #InfectiousDisease diagnostics, #STD screening, and #CervicalCancer assessments, each application unfolds a unique perspective. #Hospitals, #Clinics, #DiagnosticCentres, and even home care settings are vital end-users. 📈 Catalysts of Change: The rise of breast cancer prevalence takes centre stage, propelling the growth as a pivotal driver. This global #HealthChallenge is linked to rising #MortalityRates, emphasizing the urgency of early detection, especially among an #AgingPopulation. 🌍 Global Diagnostic Momentum: A conspicuous trend emerges—the global embrace of advanced diagnostic solutions. #Immunoassay and #MolecularDiagnostics play key roles in breast cancer management and infectious disease testing. The drive for tailored automation solutions underscores a forward-thinking landscape. ⚙️ Navigating Challenges: Challenges are inherent, including the shortage of skilled #laboratory technicians. Precision demands hands skilled in immunoassays and molecular diagnoses. Proficiency with advanced diagnostic devices is pivotal, ensuring accuracy in results. 🔬 Excellence in Expertise: Expertise remains non-negotiable, safeguarding against data errors and misguided #diagnoses. The pursuit of dependable results rests on professionals adept at navigating automated systems. 🌟 Ready to Explore Further? Embrace the evolving landscape of the women's health diagnostics market. Gain insights from our sample report: https://lnkd.in/gzS8R_5J #WomensHealthDiagnostics #MarketExploration #HealthcareInsights

𝗪𝗼𝗺𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟮. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The women’s health diagnostics market is a crucial sector within healthcare, dedicated to addressing women's unique healthcare needs throughout their lives. It encompasses various diagnostic #technologies, services, and products aimed at detecting, monitoring, and managing conditions specific to women's health. Growth in this market is driven by factors such as increasing awareness and prioritization of gender-specific health needs, along with a rising focus on preventive healthcare, leading more women to seek diagnostic services. Technological advancements, including innovations in diagnostic imaging, in vitro diagnostics, and #genetictesting, contribute significantly to the market's expansion, enhancing precision and efficiency. Integration of advanced technologies like molecular diagnostics and point-of-care testing further fuels market growth, while #collaborative efforts between healthcare professionals, researchers, and industry stakeholders drive the development of novel diagnostic solutions. Additionally, the market benefits from a holistic approach to women's health, incorporating comprehensive disease-specific diagnostics tailored for conditions such as breast and gynecological cancers. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝗰𝗼𝗽𝗲 𝗮𝗻𝗱 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗪𝗼𝗺𝗲𝗻'𝘀 𝗛𝗲𝗮𝗹𝘁𝗵 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗠𝗮𝗿𝗸𝗲𝘁.𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/gaPP9nRB *𝗕𝘆 𝗧𝘆𝗽𝗲: Cancer, Infectious disease, Osteoporosis, Pregnancy & fertility, Prenatal *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Laboratory, Home Care, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: F. Hoffmann-la Roche Ltd., Siemens Aktiengesellschaft, Quest Diagnostics, GE HealthCare, Koninklijke Philips N.V., Abbott Laboratories, Becton, Dickinson, and Company,, Hologic, Inc., #womenshealth #healthdiagnostics #medicaldiagnostics #womenshealthcare #diagnosticimaging #healthscreening #womenshealthawareness #preventivehealth #healthcaretechnology #medicaldevices #healthcareindustry #healthcareinnovation #healthtech #digitalhealth #healthylifestyle #patientcare #healthawareness #publichealth #womenwellness #healtheducation

We don't all have the same chances when it comes to breast cancer. Diversity in clinical trials is not just a matter of fairness—it's a critical factor in advancing effective and equitable healthcare. Different populations can respond differently to the same treatment due to genetic, environmental, and lifestyle factors. Without diverse representation, clinical trials risk excluding key demographic groups, leading to significant gaps in our understanding of how treatments work across varied populations. For too long, certain groups have been underrepresented in medical research, resulting in disparities in health outcomes. These gaps mean that the treatments and interventions developed may not be as effective or safe for everyone. By prioritizing diversity in clinical trials, we can work towards eliminating these disparities, ensuring that medical research benefits everyone, regardless of their background. Incorporating diverse populations in clinical trials leads to more comprehensive data, which enhances our ability to develop treatments that are safe, effective, and tailored to the needs of all patients. This commitment to diversity not only improves individual health outcomes but also strengthens the overall healthcare system by fostering innovation and inclusivity. #BIGagainstBC #BreastCancer #BreastCancerResearch #EU4Health European Health and Digital Executive Agency (HaDEA)

The projected growth of the global women's health diagnostics market to reach USD 31.4 billion by 2030, with an estimated CAGR of 7.3% from 2023 to 2030, reflects promising advancements in the sector. This expansion is attributed to the increasing adoption of point-of-care diagnostics and the rising incidence of chronic and lifestyle-related diseases among women. The introduction of diverse awareness programs focusing on women's health is poised to significantly contribute to market growth during the forecast period. These initiatives aim to educate and empower women about the importance of early diagnosis, preventive healthcare measures, and access to advanced diagnostic technologies, consequently driving the market's development and enhancing overall healthcare outcomes for women worldwide. #WomensHealth #Healthcare #PreventiveHealthcare

🌐 #FemTech: Bridging Gaps in Women's Healthcare 🌐 The FemTech industry is gaining deserved attention for its role in shaping women's health. It's more than just a buzzword; it's a promise to address long-standing challenges and prejudices faced by women in healthcare. As someone both in the professional realm and personally as an endometriosis patient, the significance of breaking these barriers resonates deeply with me. At Evolv Health, our mission is clear: Integrate the potential of data-driven digital healthcare and the therapeutic properties of cannabinoid prescription medication to address the vast spectrum of female pain. And we've kickstarted this journey with a focus on endometriosis 💪. Together, let's redefine healthcare for every woman out there. Every step counts! #WomensHealth #EvolvHealthcare #DigitalMedication #EndometriosisAwareness #womenhealthcare #Femtech https://lnkd.in/dB9hrc9e

🌟Research Opportunity: Understanding LGI1 AIE Patient Journey 🌟 We’re excited to share that Alira Health is conducting a research study to delve into the emotional and cost aspects of living with Leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1 AIE). This research aims to provide a deeper understanding of the challenges faced by LGI1 AIE patients. 🔍 Study Goals: 1 - Describe emotional and cost elements of the LGI1 AIE patient journey. 2 – Quantify the burden of LGI1 AIE on patients. 3 – Identify unmet needs in the patient journey. 4 – Understand the impact on quality of life. 🧑🔬 Participant Criteria: If your 18+, officially diagnosed with LGI1 AIE, and based in Germany, France, Spain, or Italy, we invite you to participate! 🤝 What’s Involved: Participants will have a 60 – 90 min remote interview followed by a short survey. Reimbursement is available based on your country. 📅 Dates: 1-30 November, with flexible scheduling options. ⏰ Deadline to reach out: 20 November 2023 For more details or to participate, please contact Dr. Eduardo Perez and Melchior Perella-Savarese at eduardo.perez@alirahealth.com and melchior.perellasavarese@alirahealth.com https://bit.ly/47i8ucs Let’s work together to shed light on LGI1 AIE patient experiences! 🌟

Genetesis, another CincyTech portfolio company, has been selected for Spoke Membership in the ARPA-H Investor Catalyst Hub. This membership offers new access to potential funding and opportunities to meaningfully influence how ARPA-H addresses key challenge areas. Intended to catalyze innovative solutions and help make them broadly available to all Americans, the Investor Catalyst Hub is one of the three key regional hubs that form the foundation for ARPANET-H, ARPA-H’s national health innovation network. Genetesis’s acceptance into the Investor Catalyst Hub comes at a time of increased focus on women’s health research and outcomes. Most recently, First Lady Dr. Jill Biden announced the ARPA-H Sprint for Women’s Health, a commitment of $100 million in funding for transformative research and solutions supporting key women’s health initiatives. Genetesis is committed to contributing to the elimination of disparities in cardiovascular outcomes between men and women since initiating research into coronary microvascular dysfunction (CMD). They are revolutionizing the standard of care for ischemic heart disease with the world's first clinically ready MCG machine. ⭐ A message you'll continue to see woven throughout the CincyTech portfolio, Genetesis is another company that's paving the way for groundbreaking advancements in healthcare. Congrats to the Genetesis team on this achievement! https://lnkd.in/g-yV9Sqh #Healthcare #HealthcareInnovation #HeartHealth

AccendoWave - A Pain #Data Company For too long, there has been a failure to invest resources and efforts focused on female and sex-specific biology. As a result, we do not currently understand the basic biology that drives many conditions that burden women. And that lack of understanding has prevented the development of effective, precision -based therapeutics for those conditions. A Top 4 Global Health Equity Solution and Top 15 Global Remote Monitoring Company, AccendoWave, benchmarks objective brain wave pain data (specialty, gender, age) and has nine #pain databases: Emergency Department, Maternal Health, Oncology, MSK, Medical Surgical, ICU, #Women, Adults, Seniors to eliminate bias, improve outcomes and reduce health care costs. If desired, AccendoWave can also create customized pain databases for partners that can be accessed on the Datavant platform.

What shape will the future of women’s health take? Did you know that FemTech value is estimated at over $50 billion by 2025? This makes it a promising market and a real breeding ground for innovation!   At Alcimed we have been exploring the domain of women’s health for years. Recently, we have closely examined the trends and issues with the way women’s health is addressed and the current unmet needs. We have also investigated how innovative technologies can shape the future of this important therapeutic area and how this market will evolve on the years to come. Take a look! 😊 #womenshealth #femtech #women #innovation #maternity https://lnkd.in/ed-67myf https://lnkd.in/erhVeYPX https://lnkd.in/eVrzRWUQ

The collective effort and dedication of our team in developing and executing the just published paper titled "Implementing a digital solution for patients with migraine - Developing a methodology for comparing digitally delivered treatment with conventional treatment: A study protocol" fill me with immense pride. This research underscores the potential of digital health solutions to revolutionize patient outcomes and access to care in already near future. The article aims at evaluating the effectiveness of digital interventions versus traditional treatments for migraine. It involves a randomized, prospective design with up to 600 participants across eight treatment groups, which is proposed to become the standard-methodology for similar studies. This research is significant for its potential to demonstrate the viability of digital treatments in enhancing patient access to evidence-based care for chronic conditions like migraine. Its innovative methodology paves the way for significant advancements in patient care. For more detailed information, you can freely access the full article (https://lnkd.in/dP-RZehP).